Project Grant R41DK123953

This $191,064 federal Project Grant award from the Food and Drug Administration (FDA) Research program (CFDA 93.103) supports a Phase II clinical trial of the drug combination avutometinib plus defactinib for the treatment of rare, aggressive forms of thyroid cancer. The trial is being conducted by the Sloan-Kettering Institute for Cancer Research, a leading non-profit cancer research organization in New York. The study aims to evaluate the efficacy of this drug combination in treating...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports the development of a long-acting parathyroid hormone (PTH) derivative, EXT608, for the treatment of hypoparathyroidism. The $999,615 award to Extend Biosciences Inc., a woman-owned small business, will fund a Phase 2 clinical trial to evaluate the safety, tolerability, and efficacy of...

The federal Project Grant award R01DK140455 in the amount of $333,000.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award supports a randomized, three-arm, double-blind, controlled, escalating dose parallel pilot study to evaluate the safety and efficacy of once-daily versus twice-daily administration of levothyroxine (LT4) and liothyronine (LT3)...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports the development of a novel therapeutic antibody for the treatment of acromegaly. Acromegaly is a rare endocrine disorder that leads to excess growth hormone production and serious health complications. The $1,035,589 award, spanning September 2024 to July 2026, aims to prepare the...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $440,333 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Brigham Young University to develop a novel Chimeric Autoantigen Receptor (CAAR) T cell therapy for the treatment of Graves' disease. The goal of this 3-year research project is to characterize the CAAR T cell technology and evaluate its efficacy and specificity in eliminating autoreactive B cells that produce antibodies...

This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports a research project titled "Redefining and Improving Hypothyroidism Care Using Real-World Data." The $172,003 award aims to determine the association between cumulative thyroid-stimulating hormone (TSH) control and cardiovascular outcomes in patients with...

The National Cancer Institute (NCI) awarded a $219,351 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Institute For Cancer Research to assess the efficacy and toxicity of T3, the active form of thyroid hormone, as a potential treatment for medulloblastoma, the most common malignant brain tumor in children. The two-year project aims to: Evaluate the toxicity, pharmacokinetics, and pharmacodynamics of T3 in tumor-bearing mice, and Examine the therapeutic efficacy of T3 in...

This federal Project Grant award of $559,587.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to investigate how thyroid hormone (TH) can suppress the growth of medulloblastoma (MB), the most common malignant brain tumor in children. The research aims to elucidate the mechanisms by which TH induces terminal differentiation of MB cells, thereby inhibiting their tumorigenic potential and repressing MB tumor growth. Key research activities include...

The National Institutes of Health's National Center for Advancing Translational Sciences (NCATS) awarded a $145,636 project grant (CFDA 93.350) to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to evaluate the relationship between thyroid hormone levels and brown adipose tissue activity, transcriptome, and cellular composition in adult humans. The study aims to better understand the interaction between the thyroid axis and brown adipose tissue in the process of thermogenesis and energy...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $298,883 to Iaterion, Inc. to develop a safer menopausal hormone therapy (MHT) formula that can be used long-term to treat protracted menopausal symptoms and prevent chronic diseases like osteoporosis, diabetes, obesity, and metabolic syndrome. The project aims to create an estradiol/reprogramming ligand combination that can potentially replace the progestin component of current MHT...